Cadila Healthcare Limited has informed the Exchange regarding a press release dated December 13, 2021, titled "Zydus to begin Phase II (a) clinical trial of ZYIL1, a novel oral NLRP3 inflammasome inhibitor in patients with Cryopyrin-Associated Periodic Syndrome (CAPS) in Australia".